Alec Jamieson1, Alicia M Goodwill2, Mario Termine1, Stephen Campbell3, Cassandra Szoeke4. 1. Centre for Medical Research, Royal Melbourne Hospital, Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia. 2. Centre for Medical Research, Royal Melbourne Hospital, Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia; Healthy Brain Initiative, Faculty of Health Sciences, Australian Catholic University, Melbourne, Victoria, Australia. 3. Australian Healthy Ageing Organisation (AHAO), Parkville, Victoria, Australia. 4. Centre for Medical Research, Royal Melbourne Hospital, Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia; Healthy Brain Initiative, Faculty of Health Sciences, Australian Catholic University, Melbourne, Victoria, Australia; Australian Healthy Ageing Organisation (AHAO), Parkville, Victoria, Australia. Electronic address: cszoeke@unimelb.edu.au.
Abstract
BACKGROUND: Depression's relationship with cerebral abnormalities and cognitive decline is temporally dynamic. Despite clear clinical utility, understanding depression's effect on cerebral structures, cognitive impairment and the interaction between these symptoms has had limited consideration. METHODS: This review summarised studies examining a clinical depression diagnosis or validated scales measuring depressive symptoms, data concerning amyloid-beta (Aβ) levels, brain structure and function focusing on hippocampal alterations, or white matter hyperintensities (WMH), and at least one validated neuropsychological test. Online database searches of: PsycINFO, EMBASE, MEDLINE, and Scopus were conducted to identify potential articles. RESULTS: While depression was consistently associated with cross-sectionally cognitive decline across multiple domains, the neuropathological basis of this dysfunction remained unclear. Hippocampal, frontal, and limbic dysfunction as well as cortical thinning, WMH, and Aβ burden all provide inconsistent findings, likely due to depression subtypes. The consistency of these findings additionally decreases when examining this relationship longitudinally, as these results are further confounded by pre-dementia states. The therapeutic interventions examined were more efficacious in the younger compared with the older samples, who were characterised by greater WMH and Aβ burden. LIMITATIONS: The limited number of longitudinal and interventional studies in addition to the heterogeneity of the samples restricts their generalisability. CONCLUSIONS: Symptomatological differences between early-onset and late-onset depression (EOD and LOD) appear crucial in understanding whether late-life depression is the primary or secondary source of cerebral pathology. Though severe cognitive impairments and clearer neuropathological underpinnings are more characteristic of LOD than EOD, the inconsistency of valid biomarkers remains problematic.
BACKGROUND:Depression's relationship with cerebral abnormalities and cognitive decline is temporally dynamic. Despite clear clinical utility, understanding depression's effect on cerebral structures, cognitive impairment and the interaction between these symptoms has had limited consideration. METHODS: This review summarised studies examining a clinical depression diagnosis or validated scales measuring depressive symptoms, data concerning amyloid-beta (Aβ) levels, brain structure and function focusing on hippocampal alterations, or white matter hyperintensities (WMH), and at least one validated neuropsychological test. Online database searches of: PsycINFO, EMBASE, MEDLINE, and Scopus were conducted to identify potential articles. RESULTS: While depression was consistently associated with cross-sectionally cognitive decline across multiple domains, the neuropathological basis of this dysfunction remained unclear. Hippocampal, frontal, and limbic dysfunction as well as cortical thinning, WMH, and Aβ burden all provide inconsistent findings, likely due to depression subtypes. The consistency of these findings additionally decreases when examining this relationship longitudinally, as these results are further confounded by pre-dementia states. The therapeutic interventions examined were more efficacious in the younger compared with the older samples, who were characterised by greater WMH and Aβ burden. LIMITATIONS: The limited number of longitudinal and interventional studies in addition to the heterogeneity of the samples restricts their generalisability. CONCLUSIONS: Symptomatological differences between early-onset and late-onset depression (EOD and LOD) appear crucial in understanding whether late-life depression is the primary or secondary source of cerebral pathology. Though severe cognitive impairments and clearer neuropathological underpinnings are more characteristic of LOD than EOD, the inconsistency of valid biomarkers remains problematic.
Authors: D E Anderson; V R Bhatt; K Schmid; S A Holstein; M Lunning; A M Berger; M Rizzo Journal: Clin Neurophysiol Date: 2019-05-24 Impact factor: 3.708
Authors: Meichen Yu; Nicholas Cullen; Kristin A Linn; Desmond J Oathes; Darsol Seok; Philip A Cook; Romain Duprat; Irem Aselcioglu; Tyler M Moore; Christos Davatzikos; Maria A Oquendo; Myrna M Weissman; Russell T Shinohara; Yvette I Sheline Journal: Mol Psychiatry Date: 2021-02-15 Impact factor: 13.437
Authors: Gwenn S Smith; Hiroto Kuwabara; Ayon Nandi; Neda F Gould; Najilla Nassery; Alena Savonenko; Jin Hui Joo; Michael Kraut; James Brasic; Daniel P Holt; Andrew W Hall; William B Mathews; Robert F Dannals; Dimitrios Avramopoulos; Clifford I Workman Journal: Neurobiol Aging Date: 2021-01-15 Impact factor: 5.133
Authors: Gwenn S Smith; Hiroto Kuwabara; Neda F Gould; Najilla Nassery; Alena Savonenko; Jin Hui Joo; Kristin L Bigos; Michael Kraut; James Brasic; Daniel P Holt; Andrew W Hall; William B Mathews; Robert F Dannals; Ayon Nandi; Clifford I Workman Journal: Neuropharmacology Date: 2021-01-12 Impact factor: 5.273
Authors: Jennifer T Sneider; Julia E Cohen-Gilbert; Derek A Hamilton; Anna M Seraikas; Emily N Oot; Eleanor M Schuttenberg; Lisa D Nickerson; Marisa M Silveri Journal: Psychiatry Res Neuroimaging Date: 2020-10-09 Impact factor: 2.376